BioCryst Pharmaceuticals (BCRX) Financials

$9.96

$-0.13 (-1.29%)

As on 04-Sep-2026 16:00EDT

Market cap

$2,545 Mln

Revenue (TTM)

$941 Mln

P/E Ratio

--

P/B Ratio

56.6

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Operating Revenue	940.61	874.84	450.71	331.41	270.83	157.17
Cost of Revenue	719.42	19.08	12.49	4.66	6.59	7.26
Gross Profit	221.20	855.76	438.23	326.75	264.23	149.91
Operating Expenses	534.75	514.77	440.77	430.46	412.67	327.63
Operating Profit (EBIT)	-313.16	340.99	-2.54	-103.71	-148.44	-177.72
Other Income	--	--	--	--	--	55.14
Profit before Tax	-381.19	267.39	-86.95	-226.23	-244.38	-181.81
Provision for Tax	3.49	3.53	1.93	0.31	2.73	2.25
Profit after Tax (Net Income)	-384.67	263.86	-88.88	-226.54	-247.12	-184.06
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	-247.12	-184.06

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Shareholder's Funds	-454.29	-119.15	-475.93	-455.53	-294.60	-106.99
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	803.29	437.25	805.97	822.50	739.08	591.42
Current Liabilities	208.85	196.07	160.38	149.99	105.51	103.72
Total Liabilities	766.70	514.16	490.42	516.96	550.00	588.15

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Non-Current Assets	73.17	109.81	68.45	20.99	33.50	22.02
Current Assets	484.68	404.35	421.97	495.97	516.50	566.14
Total Assets	766.70	514.16	490.42	516.96	550.00	588.15
Total Debt*	409.86	438.87	841.42	825.15	741.45	593.24
Net Current Assets	275.84	208.28	261.58	345.98	410.99	462.42

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Cash From Operating Activities	--	329.88	-52.02	-95.14	-161.85	-142.16
Cash Flow from Investing Activities	--	-13.69	52.59	-131.50	-128.24	15.80
Cash from Financing Activities	--	-332.44	-5.76	32.49	88.03	359.67
Net Cash Inflow / Outflow	--	--	--	--	--	233.39

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Adjusted EPS ($)	-1.50	1.20	-0.43	-1.12	-1.32	-1.01
Cash EPS ($)	--	1.21	-0.42	-1.12	-1.31	-1.01
Adjusted Book Value ($)	--	--	--	--	--	--
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	1.50	-0.25	-0.47	-0.87	-0.78
Free Cash Flow per Share ($)	--	1.49	-0.26	-0.48	-0.87	-0.79

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
ROCE (%)	--	77.02	-24.18	-55.49	-52.97	-59.58
ROE (%)	--	-88.68	19.08	60.40	123.07	291.59
ROA (%)	-54.91	52.53	-17.65	-42.46	-43.42	-39.89
EBIT Margin (%)	-32.84	39.58	2.57	-35.60	-53.65	-77.95
Net Margin (%)	-40.90	30.16	-19.72	-68.36	-91.24	-86.69
Cash Profit Margin (%)	0.00	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Revenue Growth (%)	68.72	0.94	0.36	0.22	0.72	7.82
EBIT Growth (%)	-596.96	2,894.84	109.80	18.79	-18.59	27.21
Net Profit Growth (%)	-977.18	396.87	60.77	8.33	-34.26	-0.68
EPS Growth (%)	-765.57	3.81	0.62	0.15	-0.31	0.02
Book Value Growth (%)	10.64	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Price / Earnings	--	6.48	-17.55	-5.33	-8.68	-13.68
Price / Book Value	56.59	-14.35	-3.28	-2.65	-7.28	-23.54
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	7.17	5.39	162.39	-14.12	-17.12	-21.39
Close Price ($)	10.00	7.80	7.52	5.99	11.48	13.85
High Price ($)	10.94	11.31	8.88	12.08	19.99	18.48
Low Price ($)	6.00	6.00	4.03	4.83	7.61	7.27
Market Cap ($ Cr)	2,545.13	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debt to Equity	-1.71	-3.68	-1.77	-1.81	-2.52	-5.55
Short term debt to equity ratio	-0.01	-0.01	-0.07	-0.01	-0.01	-0.02
Current Ratio	2.32	2.06	2.63	3.31	4.90	5.46
Quick Ratio	2.29	2.03	2.58	3.12	4.63	5.31
Interest Coverage	-4.06	4.39	0.12	-1.09	-1.47	-2.07

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debtors to sales (%)	11.77	12.21	17.54	17.18	18.68	18.71
Asset Turnover	1.34	1.74	0.89	0.62	0.48	0.34
Receivable days	--	38.80	55.11	59.27	53.95	44.22
Inventory Days	--	129.11	537.86	2,202.63	1,199.89	573.97
Payable days	--	263.00	475.94	1,381.11	1,167.76	1,169.59
Cash Conversion Cycle	--	-95.09	117.03	880.78	86.08	-551.39

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.